With a market cap of $63.5 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a fully integrated biotechnology company that ...

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea ...

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of ...

Similar to Eylea, Vabysmo is approved for a range of retinal diseases but has higher uptake due to the longer intervals between injections ... was lower than Vabysmo. Regeneron and Bayer are ...

Bayer announces EMA committee recommends label extension approval for Eylea 8 mg: Berlin Monday, May 26, 2025, 17:00 Hrs [IST] Bayer announced that the Committee for Medicinal Pro ...

following three initial monthly injections, for both nAMD and DME. Bayer’s HealthCare unit co-develops Eylea with Regeneron REGN. REGN records net product sales of Eylea in the United States ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...

Eylea, an injection against the leading causes of ... Bayer has developed it jointly with Regeneron (REGN.O), opens new tab. Vabysmo, a major driver of revenue growth for Switzerland's Roche ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...